Arrowhead Pharmac…
USUSDArrowhead Pharmaceuticals Inc (LSE:0HI3) — Biotechnology: Pharmaceutical Preparations. Anzahl der Börsen, an denen die Aktien des Unternehmens gehandelt werden: 2. Auf dieser Seite: Kurs und Chart, Dividenden, größte Aktionäre und Entwicklung der Aktienanzahl.
Über das Unternehmen
- Website
- arrowheadpharma.com
- Sektor
- Health Care · Biotechnology: Pharmaceutical Preparations
- Hauptsitz
- Pasadena, United States
- CEO
- Christopher R. Anzalone
- Mitarbeiter
- 711
- Gegründet
- 2004
- Ausstehende Aktien
- 141.25 Mio. Stand 2026-07-30
- Streubesitz
- 122.45 Mio.
- Marktkapitalisierung
- 9.22 Mrd. USD
- Insider
- 3.66%
- Institutionelle Anleger
- 85.47%
- Branche (SIC)
- Pharmaceutical Preparations
- ISIN
- US04280A1007
- LEI
- 549300O3CSB8T7OZ3D66
- FCF
- −75.1 Mio. USD
- Schulden
- 181 Mio. USD
- Gewinne und FCF – für die 12 Monate bis 30.06.2026 (aktueller Bericht des Unternehmens).
- NAV
Beschreibung
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
Größte Anteilseigner
| Inhaber | Anteil | Aktien | Berichtsdatum |
|---|---|---|---|
| Blackrock Inc. | 10.53% | 14.83 Mio. | 2026-06-30 |
| Avoro Capital Advisors L… | 8.06% | 11.36 Mio. | 2026-06-30 |
| FMR, LLC | 5.71% | 8.04 Mio. | 2026-06-30 |
| Vanguard Portfolio Manag… | 4.51% | 6.35 Mio. | 2026-06-30 |
| Vanguard Capital Managem… | 4.34% | 6.11 Mio. | 2026-06-30 |
| State Street Corporation | 4.04% | 5.69 Mio. | 2026-06-30 |
| iShares Trust-iShares Co… | 3.5% | 4.93 Mio. | 2026-08-31 |
| VANGUARD INDEX FUNDS-Van… | 3.01% | 4.25 Mio. | 2026-06-30 |
| NORGES BANK | 2.77% | 3.9 Mio. | 2026-06-30 |
| Invesco Ltd. | 2.76% | 3.88 Mio. | 2026-06-30 |
| ANZALONE CHRISTOPHER RIC… | ≈2.69% | 3.79 Mio. | 2026-01-02 |
| Geode Capital Management… | 2.51% | 3.53 Mio. | 2026-06-30 |
| Fred Alger Management, L… | 2.34% | 3.3 Mio. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.18% | 3.07 Mio. | 2026-06-30 |
| Fidelity Mt. Vernon Stre… | 1.81% | 2.55 Mio. | 2026-07-31 |
| Invesco Exchange-Traded… | 1.27% | 1.79 Mio. | 2026-08-31 |
| VANGUARD INDEX FUNDS-Van… | 1.26% | 1.77 Mio. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 1.15% | 1.61 Mio. | 2026-06-30 |
| SPDR SERIES TRUST-State… | 1.05% | 1.48 Mio. | 2026-08-31 |
| SPDR S&P MIDCAP 400 ETF… | 0.73% | 1.03 Mio. | 2026-08-31 |
| iShares Trust-iShares Bi… | 0.69% | 968 738 | 2026-07-31 |
| O'BRIEN PATRICK C (Chief… | ≈0.39% | 547 408 | 2026-01-06 |
| MYSZKOWSKI KENNETH ALLEN… | ≈0.32% | 455 433 | 2025-01-07 |
| HAMILTON JAMES C (Office… | ≈0.16% | 226 958 | 2026-04-23 |
| APEL DANIEL JOSEPH (Chie… | ≈0.12% | 162 905 | 2026-04-22 |
| GIVEN DOUGLAS BRUCE (Dir… | ≈0.09% | 124 167 | 2024-12-17 |
| PERRY MICHAEL S (Directo… | ≈0.08% | 111 459 | 2026-08-18 |
| FERRARI MAURO (Director) | ≈0.05% | 69 053 | 2025-12-26 |
| WADDILL WILLIAM D (Direc… | ≈0.04% | 56 563 | 2025-12-19 |
| LU HONGBO B (Director) | ≈0.04% | 52 012 | 2026-05-12 |
Mit Google Anmelden